Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Capital Expenditures (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Capital Expenditures data on record, last reported at $108000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 440.0% year-over-year to $108000.0; the TTM value through Dec 2025 reached $313000.0, down 22.33%, while the annual FY2025 figure was $313000.0, 22.33% down from the prior year.
  • Capital Expenditures reached $108000.0 in Q4 2025 per APLS's latest filing, down from $148000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $851000.0 in Q4 2022 and bottomed at $8000.0 in Q1 2025.
  • Average Capital Expenditures over 5 years is $216631.6, with a median of $148000.0 recorded in 2025.
  • Peak YoY movement for Capital Expenditures: tumbled 97.33% in 2021, then surged 4378.95% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $19000.0 in 2021, then soared by 4378.95% to $851000.0 in 2022, then tumbled by 88.84% to $95000.0 in 2023, then plummeted by 78.95% to $20000.0 in 2024, then surged by 440.0% to $108000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $108000.0 in Q4 2025, $148000.0 in Q3 2025, and $49000.0 in Q2 2025.